CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amide Technologies, a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform. The company also announced it has raised $16.5 million in total funding to date, which includes a $7.5 million Series A Extension investment closed in July 2023 led by Engine Ventures with participation from Forcefield Venture Fund.

马萨诸塞州剑桥市。-（商业新闻短讯）--酰胺技术公司是一家合成具有挑战性的肽的生物技术公司，今天宣布它已经开始将其新型肽制造平台商业化。该公司还宣布，迄今为止已筹集了1650万美元的资金，其中包括2023年7月由Engine Ventures牵头并由Forcefield Venture Fund参与的750万美元a系列延期投资。

Previous rounds included a $3.55M Series A, also led by Engine Ventures, and a $5.45M Seed Round led by Biological Engineering Ventures..

之前的几轮投资包括一轮355万美元的a系列投资（同样由Engine Ventures牵头），以及一轮545万美元的种子投资（由Biological Engineering Ventures牵头）。。

Peptides are strings of amino acids, which are the 'building blocks' of proteins. FDA approvals of peptide-based therapeutic drugs have increased significantly in recent years, given their efficacy in treating diseases such as autoimmune disorders, cancers, diabetes, and infections. New advances in structural biology, recombinant biologics, and AI-driven technologies have improved drug design and delivery methods, overcoming many previous pharmacokinetic behavior drawbacks of peptides.

肽是一连串的氨基酸，是蛋白质的“构建块”。近年来，FDA对基于肽的治疗药物的批准显着增加，因为它们在治疗自身免疫性疾病，癌症，糖尿病和感染等疾病方面具有功效。结构生物学，重组生物学和AI驱动技术的新进展改进了药物设计和递送方法，克服了肽以前的许多药代动力学行为缺陷。

Popular peptide-based drugs include Type II diabetes medications Mounjaro, Ozempic, Trulicity and Victoza, as well as osteoporosis drug Forteo and cancer treatments Lupron and Zoladex..

流行的基于肽的药物包括II型糖尿病药物Mounjaro，Ozempic，Trulicity和Victoza，以及骨质疏松症药物Forteo和癌症治疗Lupron和Zoladex。。

To develop and test peptides, biopharmaceutical companies source their materials from DNA synthesis companies that can naturally express peptides or Solid Phase Peptide Synthesis (SPPS) vendors that synthetically produce low-complexity polyamides featuring fewer than 40 amino acids. Yet, there remains a wide swath of peptides not served by this $4.7 billion industry that are too long to synthesize with traditional SPPS and impossible to obtain via biological expression.

为了开发和测试肽，生物制药公司从可以天然表达肽的DNA合成公司或固相肽合成（SPPS）供应商那里获得材料，这些供应商合成生产的低复杂度聚酰胺的氨基酸少于40个。然而，这个47亿美元的行业仍然存在大量肽，这些肽太长，无法与传统的SPP合成，也无法通过生物表达获得。

Amide is pioneering a third approach to bridge this synthesis gap..

酰胺开创了弥补这一合成差距的第三种方法。。

“Amide delivers on complex peptide orders that other vendors refuse because peptide sourcing shouldn’t stand in the way of discovery,” said Amide CEO Mark Simon, PhD. “Amide provides unprecedented access to large and unusual compounds to eliminate pain points for discovery chemistry teams and enable better, faster science.”.

Amide首席执行官Mark Simon博士说：“Amide提供了其他供应商拒绝的复杂肽订单，因为肽采购不应该阻碍发现。”。“酰胺为发现化学团队提供了前所未有的获取大型和不寻常化合物的途径，以消除痛点，并实现更好，更快的科学。”。

Developed in the Pentelute Lab within MIT’s Department of Chemistry, Amide’s complex peptide manufacturing platform expands what is possible in peptide drug design by offering reliable linear synthesis of peptides up to 120 amino acids, dramatically improving upon SPPS technology’s maximum of around 40 amino acids.

Amide的复合肽制造平台是在麻省理工学院化学系的Pentelute实验室开发的，它通过提供高达120个氨基酸的肽的可靠线性合成，扩展了肽药物设计的可能性，大大改进了SPPS技术的最大约40个氨基酸。

Amide's Automated Fast Flow Peptide Synthesis (AFPS) method uses heat and flow to enable fast, reliable synthesis of complex peptides that can’t be naturally expressed, such as mirror image proteins and branched structures..

Amide的自动快速流动肽合成（AFPS）方法利用热量和流量来快速可靠地合成无法自然表达的复杂肽，例如镜像蛋白和分支结构。。

The company can ship urgent orders within a week, empowering rapid design-build-test cycles for labs who typically wait weeks to months to test one hypothesis. For the first time, customers have routine access to highly hydrophobic peptides, cyclic constructs, branched peptides, and mirror image proteins.

该公司可以在一周内发出紧急订单，为通常需要数周至数月才能验证一个假设的实验室提供快速的设计-构建测试周期。客户首次常规获得高疏水性肽，环状构建体，分支肽和镜像蛋白。

Novel structures enable novel modalities, which means more effective clinical programs supported by Amide's synthesis capabilities..

新的结构使新的模式成为可能，这意味着由酰胺的合成能力支持的更有效的临床计划。。

“Amide is well-positioned to turbocharge today’s most exciting pharmaceutical frontiers: the search for novel therapeutic modalities with multiple biological activities, meaning more drugs that hit multiple targets,” said Reed Sturtevant, General Partner, Engine Ventures and Amide Board Member. “Previously, it could be months between an idea for a new protein and having that protein in hand – Amide is shrinking that timespan to days.

Engine Ventures普通合伙人、Amide董事会成员里德·斯特万特（Reed Sturtevant）表示：“Amide处于有利地位，可以推动当今最令人兴奋的制药前沿：寻找具有多种生物活性的新型治疗方式，这意味着更多的药物可以达到多个目标。”。“以前，从一种新蛋白质的想法到拥有这种蛋白质可能需要几个月的时间——酰胺正在将时间跨度缩短到几天。

In the world of drug discovery, timing is critical, and Amide is a powerful accelerant.”.

在药物发现的世界中，时机至关重要，酰胺是一种强大的促进剂。”。

Amide is using the funding to scale operations, build additional instrumentation, and launch new pilot programs with pharmaceutical partners. Amide currently works with organizations including The Salk Institute and Velia Therapeutics to manufacture peptides not manufacturable by other means, such as mirror image enzymes and multimeric polyamides..

Amide正在利用这笔资金扩大运营规模，建造额外的仪器，并与制药合作伙伴启动新的试点项目。Amide目前与包括Salk Institute和Velia Therapeutics在内的组织合作，生产无法通过其他方式制造的肽，例如镜像酶和多聚体聚酰胺。。

“Amide’s significant advances in peptide synthesis has allowed us to obtain synthetic versions of very long peptides which historically would have been intractable,” said Mack Flinspach, Executive Director, Protein Chemistry and Structural Biology at Velia, Inc. “The Amide team has solved several key issues with troublesome off-path reactions that can happen under standard SPPS conditions and experimental timeframes, while also providing us outstanding customer service.”.

Velia蛋白质化学和结构生物学执行董事Mack Flinspach说：“酰胺在肽合成方面的重大进展使我们能够获得历史上难以处理的超长肽的合成版本，Inc.“酰胺团队解决了在标准SPPS条件和实验时间范围内可能发生的麻烦的非路径反应的几个关键问题，同时也为我们提供了出色的客户服务。”。

Amide has made several executive hires in 2023, including CEO Simon, a Ginkgo Bioworks alum who led the MIT team that developed Amide’s platform technology from 2011 to 2017. The company also hired as COO Philip Dixon, a former CIO of Silverrail Technologies and a veteran of the Flights and M&A teams at Google, where he landed after helping shepherd ITA Software to an acquisition in 2011.

Amide在2023年雇佣了几名高管，其中包括CEO Simon，他是银杏生物工程（Ginkgo Bioworks）的校友，曾领导麻省理工学院（MIT）团队，从2011年到2017年开发了Amide的平台技术。该公司还聘请了首席运营官菲利普·迪克森（PhilipDixon），他是Silverrail Technologies的前首席信息官，也是谷歌（Google）飞行和并购团队的资深人员。2011年，他在帮助shepherd ITA Software进行收购后，在谷歌（Google）着陆。

ITA Software founder and CEO Jeremy Wertheimer is an Amide co-founder and Board Member, alongside MIT Professor of Chemistry Brad Pentelute, PhD..

ITA软件创始人兼首席执行官JeremyWertheimer是Amide联合创始人和董事会成员，与麻省理工学院化学教授BradPentelute博士一起。。

About Amide Technologies

关于Amide Technologies

Amide Technologies is a biotech startup offering on-demand complex peptide manufacturing at unprecedented speed. Through its novel manufacturing platform developed at MIT, Amide is bridging the gap between traditional solid phase peptide synthesis and biological expression, empowering scientists on the cutting edge of peptide drug design.

Amide Technologies是一家生物技术初创公司，以前所未有的速度按需生产复合肽。通过其在麻省理工学院开发的新型制造平台，酰胺弥合了传统固相肽合成与生物表达之间的差距，为肽药物设计的前沿科学家提供了力量。

To learn more about Amide, visit amidetech.com..

要了解有关酰胺的更多信息，请访问amidetech.com。。

About Engine Ventures

关于Engine Ventures

Engine Ventures is a venture capital firm investing in the next generation of Tough Tech founders: providing capital, operational expertise, and a powerful academic, commercial, and governmental network to build and scale companies unlocking massive opportunities in climate change, human health, and advanced systems.

Engine Ventures是一家风险投资公司，投资于下一代坚强的技术创始人：提供资金、运营专业知识以及强大的学术、商业和政府网络，以建立和扩大公司规模，释放气候变化、人类健康和先进系统方面的巨大机遇。

Visit www.engineventures.com to learn more..

Visit www.engineventures.com to learn more..